Login to Your Account

In The Clinic NEWS

Mast Therapeutics Inc. expects to quit development of its lead candidate, vepoloxamer, after it failed to significantly outperform a placebo in shortening the duration of VOC in the phase III trial EPIC.

Reports of a fifth patient experiencing immune-related adverse events is prompting Mirna Therapeutics Inc. to close out its phase I trial testing microRNA mimic MRX34 and to "reassess where we stand with our pipeline now," according to President and CEO Paul Lammers.

Stellar top-line phase III data for Aerie Pharmaceuticals Inc.’s potential blockbuster glaucoma candidate, Roclatan, indicated the combination therapy performed better than either of its components and could ultimately replace latanoprost as the standard of care.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: